Late-stage clinical trial failures due to safety issues create outsized damage across the healthcare system—exactly the problem ToxiProofAI is built to solve. For health economics, these failures burn hundreds of millions in avoidable R&D spend and strain already limited innovation budgets. For patients, they mean delayed access to life-saving therapies and unnecessary exposure to safety risks that surface far too late. For drug developers, late safety surprises erase years of investment, destabilize pipelines, and increase regulatory and investor pressure—making early, accurate safety insight not just valuable, but essential.
ToxiProofAI is a personalised clinical intelligence company operating upstream of trials, regulators, and prescribing. We predict drug toxicity before human exposure using biologically grounded pharmacogenomic models powered by advanced biosensors and deep toxicology expertise. We help drug developers create regulatory trust, and durable advantage—enabling safer trials, fewer late-stage failures, and faster, more confident go/no-go decisions for next-generation therapies. We are committed to personalised precision medicine safety.
Adverse drug reactions don’t just happen on paper — they happen to people. For patients, a single adverse event can trigger physical harm, emotional distress, financial strain, and fear of continuing treatment. What starts as a medical setback can ripple into missed work, reduced quality of life, and loss of trust in care. When reactions are serious, related to treatment, or unexpected, the stakes rise even higher. Understanding how adverse events are identified and escalated isn’t just regulatory—it’s patient protection. Strong pharmacovigilance puts patients first by catching risks early, improving safety decisions, and ensuring treatments are safe.
Our pharmacogenomics engine leverages genomic sequences to capture the full genetic context driving drug response and safety risk. AI-driven de-centralized federated learning insights are validated by wet-lab biosensors, anchoring predictions in real biological evidence. At the patient level, our proprietary metrics — CIS, ESS, and DDH—enable precise patient stratification while unlocking new opportunities for drug repurposing, indication selection, and indication expansion. Together, this integrated approach surfaces safety and efficacy signals early, reducing late-stage failures and enabling truly personalized therapeutics.
Our proprietary pharmacogenomics engine -where AI meets biology to uncover hidden safety signals before they reach patients.
A secure, cloud-based app that keeps patients and doctors continuously informed about a patient’s health.
Your go-to source for safety, dosing, and toxicity details about the chemicals around you.
Optimise clinical trial design and dosing strategies with predictive efficacy, safety modelling.
De-risk your pipeline with tailored PGx insights and validation biosensors for preclinical wet-lab experimentation.
Ready-to-use proprietary biosensor libraries for rapid safety and efficacy screening.
Your trusted resource for PGx science, Adverse Drug reactions (ADRs), Drug Development, safety analytics, and latest global regulatory insights.
Clear answers to your most important questions about our technology and services.
- 6th Ace Drug Discovery Summit [February 2026]
- Immuno-Oncology & Biomarker Summit [March 2026]
- BioTrinity [April 2026]
In February 2026, our CEO delivered a meaningful online career talk to students at St. George International School, sharing insights on biotechnology, AI-driven safety solutions, and careers in the biosciences industry. The session sparked thoughtful discussions and aimed to inspire the next generation of future leaders in biosciences.
Read our Linkedin post here: https://tinyurl.com/ymb53z3k
In February 2026, we participated in the AI & Big Data Expo Global in London, connecting with AI leaders, innovators, and industry experts from across the globe. It was a great opportunity to exchange ideas, explore emerging trends, and discuss potential collaborations and partnerships focused on building responsible and impactful AI solutions.
Read our Linkedin post here: https://tinyurl.com/bdz3b4ke
In January 2026, we officially launched the ToxiProofAI FlyWheelAI at DTCT conference in London. The strong engagement, meaningful discussions, and impactful demos reinforced that we’re building something truly valuable for the future of AI safety and trust, alongside industry leaders from across pharma and biotech. We’re grateful to everyone involved—especially the ToxiProofAI team—and this is just the beginning.
Read our Linkedin post here: https://tinyurl.com/3ay6j895
In December 2025, we participated in NHS Genomics Health Summit in London, connecting with scientific leaders, regulatory officers, policy makers, health economists, clinicians, genetic consultants and exploring AI-driven innovations in healthcare supporting the UK’s 10-Year Health Plan.
Read our LinkedIn post here: https://tinyurl.com/4n4nf5y4
In December 2025, we participated in The European AI Conference 2025 at the Google London office, joined roundtable discussions, built new connections in the AI community, and exchanged perspectives on emerging trends, collaboration, and responsible AI development.
Read our LinkedIn post here: https://tinyurl.com/4cerrccw
In December 2025, we participated in the Biotechgate Digital Partnering Virtual Event 2025, engaging with global biotech leaders to explore collaborations and innovation opportunities.
Read our LinkedIn post here: https://tinyurl.com/49ukz7th
In December 2025, at the UK Biobank Scientific Conference 2025 at Queen Elizabeth II centre, we were thrilled to join discussions on advancing biomedical research through privacy-preserving, federated learning from human data. It was a day of inspiring talks, meaningful connections, and exciting new collaboration opportunities.
Read our LinkedIn post here: https://tinyurl.com/bdfnsbv8
In November 2025, we participated in the NHS England Pharmacogenomics and Medicines Optimisation – Network of Excellence event at Manchester. Our CEO and Founder, Chandan Seth Nanda, discussed with participants how we are driving AI-powered innovation in pharmacogenomics to enhance personalized precision medicine safety.
Read our LinkedIn post here: https://tinyurl.com/4et7zp82
In October 2025, we attended the London Healthtech Roundtable 2025, hosted by the London Venture Capital Network—uniting investors, founders, scientists, and family offices driving the future of health and life sciences.
Read our LinkedIn post here: https://tinyurl.com/yped2a37
In October 2025, we participated in the Drug Discovery Strategy Summit in London. Chandan shared insights on fit-for-purpose data for federated AI in target, biomarker, and drug discovery.
Read our LinkedIn post here: https://tinyurl.com/ywrs2n7d
The Tree of Life is a symbol found across cultures, representing connection, growth, and balance. Its roots, trunk, and branches illustrate how all life is linked through common ancestry, showing the evolution and diversification of species over time while connecting life, nature, and knowledge.
Our vision is to empower drug developers and put patients at the center of care, leveraging genomic insights and advanced clinical intelligence to create medicines that cure diseases safely, effectively, and equitably across all populations.
We believe in life’s interconnected balance —
our logo reflects the Tree of Life, symbolizing that a medicine should be a product of knowledge, action, and growth, all aimed at improving human life.
Life. Growth. ToxiProofAI.
Chandan Seth Nanda
CEO and Founder
I founded our company to ensure medicines safely heal people across all ages, diseases, drugs, demographics, and ethnicities.
